Cargando…

Efficacy and safety of XEN®—Implantation vs. trabeculectomy: Data of a “real-world” setting

OBJECTIVE: To compare surgical success, postoperative intraocular pressure and complication rates between trabeculectomy and XEN gelstent surgery in a cohort of glaucoma patients in a typical clinical setting. METHODS: A retrospective cohort study of consecutive patients with refractory open-angle g...

Descripción completa

Detalles Bibliográficos
Autores principales: Wagner, Felix Mathias, Schuster, Alexander Karl-Georg, Emmerich, Julia, Chronopoulos, Panagiotis, Hoffmann, Esther Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7170231/
https://www.ncbi.nlm.nih.gov/pubmed/32310972
http://dx.doi.org/10.1371/journal.pone.0231614
_version_ 1783523852341477376
author Wagner, Felix Mathias
Schuster, Alexander Karl-Georg
Emmerich, Julia
Chronopoulos, Panagiotis
Hoffmann, Esther Maria
author_facet Wagner, Felix Mathias
Schuster, Alexander Karl-Georg
Emmerich, Julia
Chronopoulos, Panagiotis
Hoffmann, Esther Maria
author_sort Wagner, Felix Mathias
collection PubMed
description OBJECTIVE: To compare surgical success, postoperative intraocular pressure and complication rates between trabeculectomy and XEN gelstent surgery in a cohort of glaucoma patients in a typical clinical setting. METHODS: A retrospective cohort study of consecutive patients with refractory open-angle glaucoma including patients who underwent either stand-alone XEN gelstent insertion with Mitomycin C or trabeculectomy with Mitomycin C between 2016 and 2018 at the University Eye Hospital Mainz, Germany. Primary outcome measure was the proportion of surgical success 1 year after surgery. Patients with an IOP ≤18mmHg, an intraocular pressure reduction of >20% and in no need of revision surgery or topical medication were considered a complete surgical success. If topical therapy was necessary, they were considered a qualified success. Multivariable logistic regression analysis was carried out for the primary outcome including gender, age, preoperative intraocular pressure and number of medication classes used preoperatively as adjustment variables. RESULTS: 171 eyes of 144 patients were included, including 82 eyes of 58 patients in the XEN group and 89 eyes of 86 patients in the trabeculectomy group. The primary outcome defined as the proportion of surgical success after 1 year (mean 11.1 months ± 2.2) was similar for both groups. The complete success proportion was 65.5% (95%-CI: 55.6–75.9%) in the trabeculectomy group, and 58.5% (95%-CI: 47.6–69.4%) in the XEN group and not statistically different in our analysis model (crude OR = 0.61; 95%-CI: 0.31–1.22; adjusted OR = 0.66; 95%-CI: 0.32–1.37). The intraocular pressure reduction, as secondary outcome measure, was higher in the trabeculectomy group (10.5 mmHg) compared to the XEN group (7.2 mmHg; p = 0.003) at the 12-month follow-up. CONCLUSION: Both XEN gelstent implantation and trabeculectomy show similar proportions of surgical success and of complications and are therefore both recommendable for clinical routine. However, trabeculectomy seems to be more effective in lowering intraocular pressure than the XEN implantation. A prospective randomized clinical trial is necessary to evaluate differences in the long-term clinical outcome.
format Online
Article
Text
id pubmed-7170231
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-71702312020-04-23 Efficacy and safety of XEN®—Implantation vs. trabeculectomy: Data of a “real-world” setting Wagner, Felix Mathias Schuster, Alexander Karl-Georg Emmerich, Julia Chronopoulos, Panagiotis Hoffmann, Esther Maria PLoS One Research Article OBJECTIVE: To compare surgical success, postoperative intraocular pressure and complication rates between trabeculectomy and XEN gelstent surgery in a cohort of glaucoma patients in a typical clinical setting. METHODS: A retrospective cohort study of consecutive patients with refractory open-angle glaucoma including patients who underwent either stand-alone XEN gelstent insertion with Mitomycin C or trabeculectomy with Mitomycin C between 2016 and 2018 at the University Eye Hospital Mainz, Germany. Primary outcome measure was the proportion of surgical success 1 year after surgery. Patients with an IOP ≤18mmHg, an intraocular pressure reduction of >20% and in no need of revision surgery or topical medication were considered a complete surgical success. If topical therapy was necessary, they were considered a qualified success. Multivariable logistic regression analysis was carried out for the primary outcome including gender, age, preoperative intraocular pressure and number of medication classes used preoperatively as adjustment variables. RESULTS: 171 eyes of 144 patients were included, including 82 eyes of 58 patients in the XEN group and 89 eyes of 86 patients in the trabeculectomy group. The primary outcome defined as the proportion of surgical success after 1 year (mean 11.1 months ± 2.2) was similar for both groups. The complete success proportion was 65.5% (95%-CI: 55.6–75.9%) in the trabeculectomy group, and 58.5% (95%-CI: 47.6–69.4%) in the XEN group and not statistically different in our analysis model (crude OR = 0.61; 95%-CI: 0.31–1.22; adjusted OR = 0.66; 95%-CI: 0.32–1.37). The intraocular pressure reduction, as secondary outcome measure, was higher in the trabeculectomy group (10.5 mmHg) compared to the XEN group (7.2 mmHg; p = 0.003) at the 12-month follow-up. CONCLUSION: Both XEN gelstent implantation and trabeculectomy show similar proportions of surgical success and of complications and are therefore both recommendable for clinical routine. However, trabeculectomy seems to be more effective in lowering intraocular pressure than the XEN implantation. A prospective randomized clinical trial is necessary to evaluate differences in the long-term clinical outcome. Public Library of Science 2020-04-20 /pmc/articles/PMC7170231/ /pubmed/32310972 http://dx.doi.org/10.1371/journal.pone.0231614 Text en © 2020 Wagner et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Wagner, Felix Mathias
Schuster, Alexander Karl-Georg
Emmerich, Julia
Chronopoulos, Panagiotis
Hoffmann, Esther Maria
Efficacy and safety of XEN®—Implantation vs. trabeculectomy: Data of a “real-world” setting
title Efficacy and safety of XEN®—Implantation vs. trabeculectomy: Data of a “real-world” setting
title_full Efficacy and safety of XEN®—Implantation vs. trabeculectomy: Data of a “real-world” setting
title_fullStr Efficacy and safety of XEN®—Implantation vs. trabeculectomy: Data of a “real-world” setting
title_full_unstemmed Efficacy and safety of XEN®—Implantation vs. trabeculectomy: Data of a “real-world” setting
title_short Efficacy and safety of XEN®—Implantation vs. trabeculectomy: Data of a “real-world” setting
title_sort efficacy and safety of xen®—implantation vs. trabeculectomy: data of a “real-world” setting
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7170231/
https://www.ncbi.nlm.nih.gov/pubmed/32310972
http://dx.doi.org/10.1371/journal.pone.0231614
work_keys_str_mv AT wagnerfelixmathias efficacyandsafetyofxenimplantationvstrabeculectomydataofarealworldsetting
AT schusteralexanderkarlgeorg efficacyandsafetyofxenimplantationvstrabeculectomydataofarealworldsetting
AT emmerichjulia efficacyandsafetyofxenimplantationvstrabeculectomydataofarealworldsetting
AT chronopoulospanagiotis efficacyandsafetyofxenimplantationvstrabeculectomydataofarealworldsetting
AT hoffmannesthermaria efficacyandsafetyofxenimplantationvstrabeculectomydataofarealworldsetting